IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Stock Information for IDEAYA Biosciences Inc.
Loading
Please wait while we load your information from QuoteMedia.